As the world watches and waits for Valeant Pharmaceuticals Intl Inc VRX 2.04%‘s next move, activist investor and new Valeant board member Bill Ackman says the move will not involve the sale of Bausch & Lomb. Ackman cleared up the Bausch & Lomb issue in an interview with CNBC following reports by FOX Business Network’s Charlie Gasparino that Valeant is “actively discussing” a Bausch & Lomb sale.

“It’s a core asset,” Ackman said of Bausch & Lomb. “We’re only considering selling non-core assets.”

As recently as March 9, prior to joining the board, Ackman raised the possibility of Valeant selling Bausch & Lomb, calling it a “very valuable standalone business” in a Bloomberg interview.

Ackman’s Valeant losses, including a reported $1 billion paper loss in one day last month, have been highly-publicized. However, Ackman’s commitment to the bull case for Valeant has never wavered. Ackman told…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!